A sodium channel enhancer, LY341311, increases myocardial contractile performance without increasing heart rate in conscious normal dogs: A comparison with dobutamine

Journal of Cardiac Failure

Volumn 8, Issue 1, 2002, Pages 33-42

  Gill, Robert M ^a   Jones, Bonita D ^a   Steinberg, Mitchell I ^a   Shen, Weiqun ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Dobutamine; Left ventricular function; LY341311; MVO2; Na+ channel enhancer

Indexed keywords

4 [3 [[1 (DIPHENYLMETHYL) 3 AZETIDINYL]OXY] 2 HYDROXYPROPOXY] 1H INDOLE 2 CARBONITRILE; BDF 9196; DOBUTAMINE; LY 341311; LY 366634; SODIUM CHANNEL; SODIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTERY DIAMETER; ARTICLE; BIOMECHANICS; CATECHOLAMINE RELEASE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; HEART CONTRACTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART PACING; HEART PERFORMANCE; HEART RATE; HEART STROKE VOLUME; HEART WORK; INOTROPISM; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; SODIUM TRANSPORT; WAKEFULNESS;

EID: 0036168660     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2002.31110     Document Type: Article

References (26)

1. The pharmacological treatment of chronic congestive heart failure
2. Inotropic therapy for the failing myocardium
3. Potential deleterious effect of inotropic agents in the therapy of chronic heart failure
4. Comparison of the cardiodynamic and metabolic effects of dobutamine with those of norepinephrine and dopamine in the isolated heart
5. Calcium sensitizing agents in heart failure
6. ++ sensitivity of contractile proteins
7. Cardiac sodium channels as targets for new inotropic agents
8. Effect of a new indol-2-carbonitrile, BDF 9148, and its two enantiomers on sodium current in rat heart cells
9. + channels as sites of action of the cardioactive agent DPI 201-106 with agonist and antagonist enantiomers
10. +-channel activators BDF 9148, BDF 9196, and BDF 9167 in human failing and nonfailing myocardium
11. Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: A comparison to its S-enantiomer BDF 9196, to its congener DPI 201-106, to norepinephrine, and to ouabain
12. Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure
13. Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reverse
14. Function and production of nitric oxide in the coronary circulation of conscious dogs during exercise
15. Effect of a novel intropic agent, BAY y 5959, in conscious dogs: Comparison with dobutamine and milrinone
16. Differential effects of BDF 9148 and DPI 201-106 on action potential and contractility in rat and guinea-pig myocardium
17. The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated heart preparations
18. Characterization of the effects of the new inotropic agent BDF 9148 in isolated papillary muscles and myocytes of the guinea-pig heart
19. 2+-exchanger in human myocardium
20. Inotropic actions of BDF 9148 and DPI 201-106 and their enantiomers in guinea-pig, rat and human atria
21. +-channel activators
22. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents
23. 2 assessment
24. Cardiac and hemodynamic effects of S(-)- and (R(+)-DPI 201-106 and of racemic DPI 201-106 in conscious dogs
25. Digoxin in heart failure: Implications of recent trials
26. Role of intracellular sodium in the regulation of intracellular calcium and contractility. Effects of DPI 201-106 on excitation-contraction coupling in human ventricular myocardium